← Oncology Approval Tracker

FDA DECISION ·

Camcevi ETM

leuprolide mesylate · Foresee Pharmaceuticals

FDA approvalNew formulationProstate cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

A three-month subcutaneous depot for adults with advanced prostate cancer.

LAMPGEN ANALYSIS

Why it matters

The 21 mg formulation adds a quarterly administration schedule for leuprolide-based androgen deprivation.

What research teams should watch

Separate three-month and six-month ordering and recall schedules and confirm correct preparation before injection.

PRIMARY RECORDS

Sources